Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company

robot
Abstract generation in progress

Wells Fargo & Company upgraded Sutro Biopharma (NASDAQ:STRO) from “Equal Weight” to “Overweight” and significantly increased its price target from $8.00 to $27.00, implying a 26.58% upside. Despite the upgrade, Sutro Biopharma reported a quarterly EPS miss of -$5.39 and continues to show negative margins and return on equity, though revenue beat estimates. The stock has a mixed analyst view with a “Hold” consensus rating and an average target price of $34.33, with institutional investors showing recent activity in their holdings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin